Eris Lifesciences Limited
ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.
What Eris files
- Investor Meet48
- Others48
- Important27
- Board Meeting18
- PPTs8
- Updates7
Eris Lifesciences posted strong Q1 FY27 results. Consolidated revenue grew 13% YoY to ₹873 Cr, with PAT up 14.5% to ₹143 Cr. Domestic Branded Formulations (DBF) revenue rose 14.2% to ₹801 Cr, with 7 of 10 therapies showing double-digit growth. Key segments like Insulin surged 27.7%, and GLP-1 (Sundae) grew...
Eris Lifesciences delivered a solid FY26, with consolidated revenue up 8.1% to Rs. 3,129 Cr and EBIDTA increasing 10.1% to Rs. 1,120 Cr, achieving a 36% margin. Domestic Branded Formulations (DBF) grew 11% to Rs. 2,778 Cr, driven by strong performance in Insulin (+32% vs market) and Derma (+14.2% vs...
Eris Lifesciences Q3 & 9M FY26 results show solid growth! **Business Performance:** Consolidated Revenue jumped 11% YoY to ₹807 Cr in Q3, with 9M revenue up 8.4% to ₹2,373 Cr. Adjusted Profit After Tax (PAT) soared 38.5% in Q3 to ₹120 Cr (9M up 39.3% to ₹380 Cr), fueled by...
**Business Performance:** Eris Lifesciences posted strong Q2 FY26 results: consolidated revenue up 7% to Rs. 792 Cr, EBIDTA up 9% to Rs. 288 Cr, and PAT soared 39% to Rs. 134 Cr. Half-year figures also impressed, with PAT jumping 40% to Rs. 260 Cr. Domestic Branded Formulations (DBF) saw robust...
Here's a summary of the investor presentation: **1. Financial Highlights:** Q1 FY26 consolidated revenue was Rs. 773 Cr. (+7.4% YoY), with Domestic Branded Formulations (DBF) growing 11% and outperforming IPM. PAT surged 41% to Rs. 125 Cr., initiating EPS acceleration. EBITDA grew 11% to Rs. 277 Cr. (35.8% margin). Debt...